Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead program, ficerafusp alfa, is a bifunctional antibody combining an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through dual-targeting mechanism, ficerafusp alfa has potential to exert potent anti-tumor activity by simultaneously blocking cancer cell-intrinsic EGFR survival and proliferation, as well as immunosuppressive TGF-β signaling within the tumor microenvironment. Lead indication is head and neck squamous cell carcinoma (HNSCC).
Public Company
Bicara Therapeutics is publicly traded
IPO'd on Sep 13, 2024
This company is no longer available on our private secondary market. Shares can be traded publicly under BCAX.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
51–200
Total Funding
$675M
5 rounds
Secondary Signals (Note: SetterVC does not verify the accuracy of these)
1 signalAnnounced President/COO Ryan Cohlhepp will succeed founder Claire Mazumdar as CEO effective Jan 1, 2027; Mazumdar to be Vice Chair.
Planned succession ahead of commercialization; low direct price impact.
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $675M across 5 rounds
Last updated 10-09-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Sep 13, 2024 | IPO | $362M | — | Not disclosed |
| Dec 12, 2023 | Series C | $165M | — | Braidwell LP, TPG |
| Mar 6, 2023 | Series B | $108M | — | Red Tree Venture Capital, RA Capital Management |
Prominent Investors
Leadership
Claire Mazumdar
Chief Executive Officer
Ryan Cohlhepp
President & Chief Operating Officer
Jenn Larson
Chief Financial Officer
Bill Schelman
Chief Medical Officer
Chris Sarchi
Chief Commercial Officer
Tanya Green
Chief Development Officer
Jenna Cohen
Chief Corporate Affairs Officer
Greg Shiferman
Chief Legal Officer
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Genmab
Danish bispecific-antibody developer that now owns petosemtamab, an EGFR x LGR5 bispecific in Phase 3 development in first-line and in second/third-line recurrent or metastatic head and neck squamous cell carcinoma - the same indication Bicara's ficerafusp alfa is pursuing, and the closest competitive read-across for Bicara's clinical data. Petosemtamab holds FDA Breakthrough Therapy designations in head and neck cancer. Genmab acquired the asset with Merus N.V. in a $97-per-share cash tender offer that completed in December 2025; Merus shares ceased trading on Nasdaq on December 30, 2025 and it is now a wholly owned Genmab subsidiary.
Bicara Therapeutics Investment FAQ
Bicara Therapeutics FAQ
Yes, Bicara Therapeutics is publicly traded under the ticker symbol BCAX on the NASDAQ. The company went public in Sep 13, 2024.
Bicara Therapeutics trades under the ticker symbol BCAX on the NASDAQ. It began trading in Sep 13, 2024.
Bicara Therapeutics (BCAX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker BCAX to place an order.
Bicara Therapeutics went public in Sep 13, 2024 via ipo. Bicara Therapeutics completed its initial public offering on Nasdaq on September 13, 2024 under the ticker BCAX, pricing an upsized offering of 20,125,000 shares at $18.00 per share for gross proceeds of approximately $362 million including full exercise of the underwriters' option. The offering closed September 16, 2024, with Morgan Stanley, TD Cowen, Cantor and Stifel as joint bookrunners. Bicara returned to the public market in February 2026, pricing an underwritten offering of 7,175,000 shares at $16.00 and pre-funded warrants for a further 2,200,000 shares; with the underwriters' option exercised in full the offering closed on February 26, 2026 for aggregate gross proceeds of approximately $172.5 million, or about $161.8 million net. The company reported cash, cash equivalents and marketable securities of $497.3 million as of June 30, 2026 and expects that to fund operations into the first half of 2029.
Bicara Therapeutics raised $675M across 5 disclosed funding rounds prior to its public listing.
Bicara Therapeutics is headquartered in Boston, MA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.